Treatment
Sirolimus clinical trials
We’re tracking 104 recruiting studies that include Sirolimus, each written for real people, not researchers, below.
Recruiting studies
- NCT06960928RecruitingPhase 3
Low dose sirolimus for long COVID
This trial tests if a low dose of sirolimus, a medicine that calms the immune system, can help people with long COVID. If you have had long COVID symptoms for at least 6 months, like severe fatigue, brain fog, or chest pain, you may be able to join.
New York, New YorkAges 18 years+ - NCT07104331RecruitingPhase 2
Testing nab-sirolimus for epithelioid hemangioendothelioma
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Stanford, CaliforniaAges 18 years+ - NCT02042326RecruitingPhase 2
Sirolimus trial for severe arteriovenous malformations
This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.
BrusselsAges 2 years+ - NCT02432560Recruiting
Testing sirolimus for long-term treatment of LAM
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
Stanford, CaliforniaAges 18 years+ - NCT02638389RecruitingPhase 3
Sirolimus for hard-to-treat vascular birthmarks
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Brussels, Brussels CapitalAges 3 months–70 years - NCT07581704RecruitingPhase 1
Sirolimus plus immunotherapy for relapsed multiple myeloma
This study tests whether a drug called sirolimus, given before certain immunotherapy treatments (teclistamab or talquetamab), helps these treatments work better against multiple myeloma. These immunotherapies teach your immune cells to attack myeloma cells.
Iowa City, IowaAges 18 years+ - NCT07656909RecruitingPhase 2/Phase 3
Comparing low and high dose sirolimus with prednisolone for KHE with KMP
This study tests whether a low dose or a high dose of sirolimus (a drug that stops abnormal cell growth) combined with prednisolone (a steroid) works better for children with a rare, aggressive vascular tumor called KHE that also causes low blood platelets (KMP). The goal is to find the safest and most effective dose to help shrink the tumor and improve blood counts.
Chengdu, SichuanAges 1 day–18 years - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT06843811Enrolling by invitationPhase 2
Sirolimus for Leigh Syndrome
This trial tests if sirolimus can help people with Leigh syndrome. It aims to see if the drug can improve neurological symptoms and is looking for participants aged 6 months to 55 years.
Philadelphia, PennsylvaniaAges 6 months–55 years - NCT06086496Enrolling by invitation
Study of a new drug-releasing stent for heart arteries
This trial tests a new type of stent (a small mesh tube) that slowly releases a medicine called sirolimus to keep your heart artery open after angioplasty. It is designed for people with narrowing in their heart arteries who need a stent.
Seoul, SeoulAges 19 years+ - NCT07426484RecruitingPhase 4
Testing cosibelimab for advanced skin cancer in specific patients
This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.
Boston, MassachusettsAges 18 years+ - NCT07190690Recruiting
Comparing two drug-coated stents for heart attack patients
This trial compares two types of drug-coated stents (one with sirolimus, one with everolimus) in people who have had a heart attack or unstable angina and need a stent. It aims to see which stent works better for new blockages in the heart arteries.
AlicanteAges 18 years+ - NCT07052929RecruitingPhase 1/Phase 2
Gene therapy study for young boys with XLMTM on ventilators
This study tests a new gene therapy called ASP2957 in young boys with X-linked myotubular myopathy who are dependent on a ventilator. The goal is to see if it can help improve their breathing and muscle strength.
Chicago, IllinoisAges Up to 3 years - NCT06168305Enrolling by invitation
Safety and effectiveness of a GENOSS stent in multiple blocked arteries
This trial tests a new drug-coated stent (GENOSS® DES) for people with blockages in multiple heart arteries. It aims to see how safe and effective the stent is for these patients.
Seoul, SeoulAges 19 years+ - NCT04083183RecruitingPhase 1/Phase 2
Testing radiation plus antibody therapy for certain non-cancer diseases
This early-phase study tests a conditioning treatment using total-body irradiation and a radioactive antibody (called astatine-211) before a stem cell transplant for non-cancer conditions. The goal is to improve how well the donor cells take hold and are tolerated.
Seattle, WashingtonAges 18–49 - NCT05351216Recruiting
Sirolimus safety with routine vaccines for a rare blood vessel tumor
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
Shanghai, Shanghai MunicipalityAges Up to 12 years - NCT03292861Enrolling by invitationPhase 2
Thymoglobulin after first heart transplant: safety and effect
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
Los Angeles, CaliforniaAges 18–70 - NCT07159087Enrolling by invitation
New drug balloon for re-narrowed stents
This trial tests a new drug-coated balloon (Genoss SCB) versus an existing one (SeQuent Please NEO) for people whose heart stents have re-narrowed. It aims to see which balloon better keeps the artery open.
Gyeonggi-doAges 19 years+ - NCT07270549RecruitingPhase 1/Phase 2
Gene therapy trial for children with CTNNB1 syndrome
This trial tests a one-time gene replacement therapy given into the fluid around the brain to help children with CTNNB1 neurodevelopmental syndrome. The goal is to see if replacing the faulty gene can improve development and reduce symptoms.
LjubljanaAges 2–12 - NCT06663696Recruiting
A study of Supraflex Cruz stents for multivessel heart disease
This trial is monitoring patients who receive Supraflex Cruz stents in multiple blocked heart arteries. It aims to gather real-world safety and effectiveness data to help improve future care.
SousseAges 18–99 - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Birmingham, AlabamaAges 13–20 - NCT06866756Recruiting
Comparing two drug-coated balloons for heart artery treatment
This trial is comparing sirolimus and paclitaxel drug-coated balloons to treat new blockages or restenosis (re-blockage) in heart arteries. It aims to see which type of balloon works better for opening arteries without leaving a metal stent behind.
Vigo, PontevedraAges 18 years+ - NCT06325709RecruitingPhase 1/Phase 2
Gene editing trial for X-linked chronic granulomatous disease
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
Bethesda, MarylandAges 18–75 - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70
Common questions
- Are there clinical trials studying Sirolimus?
- Yes. Clin2 currently lists 104 recruiting studies that include Sirolimus, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sirolimus trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sirolimus an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sirolimus or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.